Vaxart earnings release, August 6, 2026

Vaxart, Inc. (VXRT) · Form 8-K, Item 2.02 · Filed · SEC filing

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027

Cash, cash equivalents, and investments of $64.0 million as of June 30, 2026; Runway into second quarter of 2027

Live stockholder fireside chat scheduled for August 7, 2026 at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., August 6, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart" or the "Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its business update and financial results for the second quarter of 2026.

"The topline results from our 400-person sentinel cohort represent an important clinical milestone for Vaxart, demonstrating the safety of our oral pill vaccine head-to-head against an approved mRNA comparator,” said Steven Lo, Chief Executive Officer of Vaxart. “This initial dataset is encouraging and provides strong validation for the safety of our platform. We are now looking forward to sharing topline efficacy and safety data from the approximately 5,000 participants in the main study cohort in the first half of 2027."

Recent Business Highlights

COVID-19 Program Update

BARDA COVID-19 Contract Update

Financial Results for the Second Quarter Ended June 30, 2026

Stockholder Fireside Chat

Vaxart will host a live stockholder fireside chat to answer frequently asked stockholder questions on Friday, August 7, 2026 at 4:30 p.m. ET.

A live webcast of the fireside chat will be available in the Investor section on the Company’s website at www.vaxart.com. Questions may be submitted in advance to ir@vaxart.com.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands, except share and per share amounts)

Three Months Ended June 30, – 2026 – ( in thousands, except share and per share amounts )Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue27,18539,73066,41360,606
Operating expenses:Research and development33,75449,73563,16780,479
Operating expenses:General and administrative6,6034,59811,2449,665
Operating expenses:Total operating expenses40,35754,33374,41190,144
Operating expenses:Operating loss-13,172-14,603-7,998-29,538
Operating expenses:Other expense, net-293-363-259-924
Operating expenses:Loss before income taxes-13,465-14,966-8,257-30,462
Operating expenses:Provision for income taxes292058115
Operating expenses:Net loss-13,494-14,986-8,315-30,577
Operating expenses:Net loss per share, basic and diluted-0.06-0.07-0.03-0.13
Operating expenses:Shares used in computing net loss per share, basic and diluted242,165,410228,367,812241,407,592228,145,724

Balance Sheet

December 31, — Condensed Consolidated Balance Sheets (in thousands)

June 30, – 2026December 31, – 2025
(Unaudited)(Unaudited)-1
AssetsCash and cash equivalents50,92953,814
AssetsShort-term investments13,0479,993
AssetsAccounts receivable1114,564
AssetsUnbilled receivable from government contracts46,98136,781
AssetsPrepaid expenses and other assets6,29521,510
AssetsProperty and equipment, net5,5055,433
AssetsPrepaid clinical services, long-term25,21825,218
AssetsRight-of-use assets, net10,23011,432
AssetsIntangible assets, net2,4612,826
AssetsGoodwill4,5084,508
AssetsTotal assets165,185186,079
Liabilities and stockholders’ equityAccounts payable16,97221,496
Liabilities and stockholders’ equityDeferred government revenue6268
Liabilities and stockholders’ equityDeferred collaboration revenue9,24214,976
Liabilities and stockholders’ equityAccrued and other liabilities44,00048,696
Liabilities and stockholders’ equityOperating lease liability7,8078,985
Liabilities and stockholders’ equityLiability related to sale of future royalties4,7314,060
Liabilities and stockholders’ equityTotal liabilities82,81498,281
Liabilities and stockholders’ equityStockholders’ equity82,37187,798
Liabilities and stockholders’ equityTotal liabilities and stockholders’ equity165,185186,079
Full release

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” "target," "seek," "intend," "may," "predict," "project," "would," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to raise capital pursuant to the purchase agreement with LPC; Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; Vaxart’s expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the Dynavax collaboration; and Vaxart’s cash runway and anticipated funding needs. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which Vaxart operates as well as management’s current beliefs and assumptions. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this press release. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contact

Vaxart Media and Investor Relations:

FINN Partners ir@vaxart.com

Vaxart, Inc.

Condensed Consolidated Balance Sheets

Vaxart, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Vaxart earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.